PHOTODYNAMIC THERAPY WITH PHOTOSENSITIZER PHOTOLON FOR BASAL CELL CARCINOMA

<p>The short-term and long-term outcomes of treatment in 130 patients with basal cell carcinoma (T1N0M0, I stage) using photodynamic therapy with photosensitizer photolon based on chlorine e6 are represented in the article. The session of photodynamic therapy was performed 2.5-3 h after intrav...

Full description

Bibliographic Details
Main Authors: D. A. Tzerkovsky, A. N. Mazurenko, N. A. Petrovskaya, T. P. Artemyeva
Format: Article
Language:Russian
Published: Non-profit partnership for development of domestic photodynamic therapy and photodiagnosis "Russian Photodynamic Association" 2017-01-01
Series:Biomedical Photonics
Subjects:
Online Access:http://www.pdt-journal.com:80/jour/article/view/146
_version_ 1818310169234243584
author D. A. Tzerkovsky
A. N. Mazurenko
N. A. Petrovskaya
T. P. Artemyeva
author_facet D. A. Tzerkovsky
A. N. Mazurenko
N. A. Petrovskaya
T. P. Artemyeva
author_sort D. A. Tzerkovsky
collection DOAJ
description <p>The short-term and long-term outcomes of treatment in 130 patients with basal cell carcinoma (T1N0M0, I stage) using photodynamic therapy with photosensitizer photolon based on chlorine e6 are represented in the article. The session of photodynamic therapy was performed 2.5-3 h after intravenous injection of photolon at dose of 2-2.5 mg/kg using semiconductor laser (λ=660±5 nm, laser power density — from 0.1 to 0.52 W/cm2, light dose — from 50 to 300 J/cm2). Complete regression of primary and recurrent carcinomas was observed in 90.9% and 88.9% of patients, respectively. For follow-up period of 3 to 76 months the local recurrence of the tumor was in detected in 6.9% of cases. Patients, who followed the light regimen for 2–3 days after photolon administration avoiding direct sun light exposure, had no manifestation of phototoxicity. Ten patients who failed to follow the light regimen had mild hyperemia, itching and burning in the exposed skin area selflimiting in several hours. Cosmetic results of photodynamic therapy with photolon are superior to those for traditional treatment methods for this disease.</p>
first_indexed 2024-12-13T07:41:47Z
format Article
id doaj.art-2b6f74c4cd804cf39827281f0723079c
institution Directory Open Access Journal
issn 2413-9432
language Russian
last_indexed 2024-12-13T07:41:47Z
publishDate 2017-01-01
publisher Non-profit partnership for development of domestic photodynamic therapy and photodiagnosis "Russian Photodynamic Association"
record_format Article
series Biomedical Photonics
spelling doaj.art-2b6f74c4cd804cf39827281f0723079c2022-12-21T23:54:57ZrusNon-profit partnership for development of domestic photodynamic therapy and photodiagnosis "Russian Photodynamic Association"Biomedical Photonics2413-94322017-01-01611219105PHOTODYNAMIC THERAPY WITH PHOTOSENSITIZER PHOTOLON FOR BASAL CELL CARCINOMAD. A. Tzerkovsky0A. N. Mazurenko1N. A. Petrovskaya2T. P. Artemyeva3Республиканский научно-практический центр онкологии и медицинской радиологии им. Н.Н. АлександроваРеспубликанский научно-практический центр онкологии и медицинской радиологии им. Н.Н. АлександроваРеспубликанский научно-практический центр онкологии и медицинской радиологии им. Н.Н. АлександроваРеспубликанский научно-практический центр онкологии и медицинской радиологии им. Н.Н. Александрова<p>The short-term and long-term outcomes of treatment in 130 patients with basal cell carcinoma (T1N0M0, I stage) using photodynamic therapy with photosensitizer photolon based on chlorine e6 are represented in the article. The session of photodynamic therapy was performed 2.5-3 h after intravenous injection of photolon at dose of 2-2.5 mg/kg using semiconductor laser (λ=660±5 nm, laser power density — from 0.1 to 0.52 W/cm2, light dose — from 50 to 300 J/cm2). Complete regression of primary and recurrent carcinomas was observed in 90.9% and 88.9% of patients, respectively. For follow-up period of 3 to 76 months the local recurrence of the tumor was in detected in 6.9% of cases. Patients, who followed the light regimen for 2–3 days after photolon administration avoiding direct sun light exposure, had no manifestation of phototoxicity. Ten patients who failed to follow the light regimen had mild hyperemia, itching and burning in the exposed skin area selflimiting in several hours. Cosmetic results of photodynamic therapy with photolon are superior to those for traditional treatment methods for this disease.</p>http://www.pdt-journal.com:80/jour/article/view/146фотодинамическая терапияфотосенсибилизаторфотолонбазальноклеточный рак кожи.
spellingShingle D. A. Tzerkovsky
A. N. Mazurenko
N. A. Petrovskaya
T. P. Artemyeva
PHOTODYNAMIC THERAPY WITH PHOTOSENSITIZER PHOTOLON FOR BASAL CELL CARCINOMA
Biomedical Photonics
фотодинамическая терапия
фотосенсибилизатор
фотолон
базальноклеточный рак кожи.
title PHOTODYNAMIC THERAPY WITH PHOTOSENSITIZER PHOTOLON FOR BASAL CELL CARCINOMA
title_full PHOTODYNAMIC THERAPY WITH PHOTOSENSITIZER PHOTOLON FOR BASAL CELL CARCINOMA
title_fullStr PHOTODYNAMIC THERAPY WITH PHOTOSENSITIZER PHOTOLON FOR BASAL CELL CARCINOMA
title_full_unstemmed PHOTODYNAMIC THERAPY WITH PHOTOSENSITIZER PHOTOLON FOR BASAL CELL CARCINOMA
title_short PHOTODYNAMIC THERAPY WITH PHOTOSENSITIZER PHOTOLON FOR BASAL CELL CARCINOMA
title_sort photodynamic therapy with photosensitizer photolon for basal cell carcinoma
topic фотодинамическая терапия
фотосенсибилизатор
фотолон
базальноклеточный рак кожи.
url http://www.pdt-journal.com:80/jour/article/view/146
work_keys_str_mv AT datzerkovsky photodynamictherapywithphotosensitizerphotolonforbasalcellcarcinoma
AT anmazurenko photodynamictherapywithphotosensitizerphotolonforbasalcellcarcinoma
AT napetrovskaya photodynamictherapywithphotosensitizerphotolonforbasalcellcarcinoma
AT tpartemyeva photodynamictherapywithphotosensitizerphotolonforbasalcellcarcinoma